BIOMAT Database Logo BIOMAT Database Logo

Structure-Activity Relationship Study of Indolin-5-yl-cyclopropanamine Derivatives as Selective Lysine Specific Demethylase 1 (LSD1) Inhibitors. 2022

Chunpu Li, and Mingbo Su, and Wei Zhu, and Weijuan Kan, and Tianpeng Ge, and Gaoya Xu, and Shuni Wang, and Li Sheng, and Feng Gao, and Yunfei Ye, and Jiang Wang, and Yubo Zhou, and Jia Li, and Hong Liu
State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China.

LSD1 is identified as an essential drug target, which is closely correlated to the development of several tumor types. In this work, on the basis of comprehensive analysis of the binding site of LSD1 and other FAD-dependent enzymes, a novel series of potent and selective LSD1 inhibitors were designed by incorporation of privileged indoline scaffold strategies. Representative compound 7e (LSD1; IC50 = 24.43 nM, selectivity over LSD2 and MAOs of >200- and 4000-fold) possessed selective antiproliferative activities against MV-4-11 cell lines. Further study indicates that 7e could activate CD86 expression (EC50 = 470 nM) and induce differentiation of AML cell lines. More importantly, compound 7e demonstrated an acceptable oral PK profile and good in vivo antitumor efficacy with a T/C value of 30.89% in an MV-4-11 xenograft mouse model. Collectively, this work provides a promising lead compound for the development of novel LSD1 inhibitors for the treatment of AML.

UI MeSH Term Description Entries
D007211 Indoles Benzopyrroles with the nitrogen at the number one carbon adjacent to the benzyl portion, in contrast to ISOINDOLES which have the nitrogen away from the six-membered ring.
D008239 Lysine An essential amino acid. It is often added to animal feed. Enisyl,L-Lysine,Lysine Acetate,Lysine Hydrochloride,Acetate, Lysine,L Lysine
D004791 Enzyme Inhibitors Compounds or agents that combine with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction. Enzyme Inhibitor,Inhibitor, Enzyme,Inhibitors, Enzyme
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000970 Antineoplastic Agents Substances that inhibit or prevent the proliferation of NEOPLASMS. Anticancer Agent,Antineoplastic,Antineoplastic Agent,Antineoplastic Drug,Antitumor Agent,Antitumor Drug,Cancer Chemotherapy Agent,Cancer Chemotherapy Drug,Anticancer Agents,Antineoplastic Drugs,Antineoplastics,Antitumor Agents,Antitumor Drugs,Cancer Chemotherapy Agents,Cancer Chemotherapy Drugs,Chemotherapeutic Anticancer Agents,Chemotherapeutic Anticancer Drug,Agent, Anticancer,Agent, Antineoplastic,Agent, Antitumor,Agent, Cancer Chemotherapy,Agents, Anticancer,Agents, Antineoplastic,Agents, Antitumor,Agents, Cancer Chemotherapy,Agents, Chemotherapeutic Anticancer,Chemotherapy Agent, Cancer,Chemotherapy Agents, Cancer,Chemotherapy Drug, Cancer,Chemotherapy Drugs, Cancer,Drug, Antineoplastic,Drug, Antitumor,Drug, Cancer Chemotherapy,Drug, Chemotherapeutic Anticancer,Drugs, Antineoplastic,Drugs, Antitumor,Drugs, Cancer Chemotherapy
D013329 Structure-Activity Relationship The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups. Relationship, Structure-Activity,Relationships, Structure-Activity,Structure Activity Relationship,Structure-Activity Relationships
D015470 Leukemia, Myeloid, Acute Clonal expansion of myeloid blasts in bone marrow, blood, and other tissue. Myeloid leukemias develop from changes in cells that normally produce NEUTROPHILS; BASOPHILS; EOSINOPHILS; and MONOCYTES. Leukemia, Myelogenous, Acute,Leukemia, Nonlymphocytic, Acute,Myeloid Leukemia, Acute,Nonlymphocytic Leukemia, Acute,ANLL,Acute Myelogenous Leukemia,Acute Myeloid Leukemia,Acute Myeloid Leukemia with Maturation,Acute Myeloid Leukemia without Maturation,Leukemia, Acute Myelogenous,Leukemia, Acute Myeloid,Leukemia, Myeloblastic, Acute,Leukemia, Myelocytic, Acute,Leukemia, Myeloid, Acute, M1,Leukemia, Myeloid, Acute, M2,Leukemia, Nonlymphoblastic, Acute,Myeloblastic Leukemia, Acute,Myelocytic Leukemia, Acute,Myelogenous Leukemia, Acute,Myeloid Leukemia, Acute, M1,Myeloid Leukemia, Acute, M2,Nonlymphoblastic Leukemia, Acute,Acute Myeloblastic Leukemia,Acute Myeloblastic Leukemias,Acute Myelocytic Leukemia,Acute Myelocytic Leukemias,Acute Myelogenous Leukemias,Acute Myeloid Leukemias,Acute Nonlymphoblastic Leukemia,Acute Nonlymphoblastic Leukemias,Acute Nonlymphocytic Leukemia,Acute Nonlymphocytic Leukemias,Leukemia, Acute Myeloblastic,Leukemia, Acute Myelocytic,Leukemia, Acute Nonlymphoblastic,Leukemia, Acute Nonlymphocytic,Leukemias, Acute Myeloblastic,Leukemias, Acute Myelocytic,Leukemias, Acute Myelogenous,Leukemias, Acute Myeloid,Leukemias, Acute Nonlymphoblastic,Leukemias, Acute Nonlymphocytic,Myeloblastic Leukemias, Acute,Myelocytic Leukemias, Acute,Myelogenous Leukemias, Acute,Myeloid Leukemias, Acute,Nonlymphoblastic Leukemias, Acute,Nonlymphocytic Leukemias, Acute
D049109 Cell Proliferation All of the processes involved in increasing CELL NUMBER including CELL DIVISION. Cell Growth in Number,Cellular Proliferation,Cell Multiplication,Cell Number Growth,Growth, Cell Number,Multiplication, Cell,Number Growth, Cell,Proliferation, Cell,Proliferation, Cellular
D051379 Mice The common name for the genus Mus. Mice, House,Mus,Mus musculus,Mice, Laboratory,Mouse,Mouse, House,Mouse, Laboratory,Mouse, Swiss,Mus domesticus,Mus musculus domesticus,Swiss Mice,House Mice,House Mouse,Laboratory Mice,Laboratory Mouse,Mice, Swiss,Swiss Mouse,domesticus, Mus musculus

Related Publications

Chunpu Li, and Mingbo Su, and Wei Zhu, and Weijuan Kan, and Tianpeng Ge, and Gaoya Xu, and Shuni Wang, and Li Sheng, and Feng Gao, and Yunfei Ye, and Jiang Wang, and Yubo Zhou, and Jia Li, and Hong Liu
Nonpeptidic propargylamines as inhibitors of lysine specific demethylase 1 (LSD1) with cellular activity.
September 2013, Journal of medicinal chemistry,
Chunpu Li, and Mingbo Su, and Wei Zhu, and Weijuan Kan, and Tianpeng Ge, and Gaoya Xu, and Shuni Wang, and Li Sheng, and Feng Gao, and Yunfei Ye, and Jiang Wang, and Yubo Zhou, and Jia Li, and Hong Liu
Structure-based design and discovery of potent and selective lysine-specific demethylase 1 (LSD1) inhibitors.
January 2019, Bioorganic & medicinal chemistry letters,
Chunpu Li, and Mingbo Su, and Wei Zhu, and Weijuan Kan, and Tianpeng Ge, and Gaoya Xu, and Shuni Wang, and Li Sheng, and Feng Gao, and Yunfei Ye, and Jiang Wang, and Yubo Zhou, and Jia Li, and Hong Liu
A Structure-Activity Relationship Study of SNAIL1 Peptides as Inhibitors of Lysine-Specific Demethylase 1.
January 2024, Chemical & pharmaceutical bulletin,
Chunpu Li, and Mingbo Su, and Wei Zhu, and Weijuan Kan, and Tianpeng Ge, and Gaoya Xu, and Shuni Wang, and Li Sheng, and Feng Gao, and Yunfei Ye, and Jiang Wang, and Yubo Zhou, and Jia Li, and Hong Liu
Fluorinated tranylcypromine analogues as inhibitors of lysine-specific demethylase 1 (LSD1, KDM1A).
May 2017, Bioorganic & medicinal chemistry letters,
Chunpu Li, and Mingbo Su, and Wei Zhu, and Weijuan Kan, and Tianpeng Ge, and Gaoya Xu, and Shuni Wang, and Li Sheng, and Feng Gao, and Yunfei Ye, and Jiang Wang, and Yubo Zhou, and Jia Li, and Hong Liu
Development of 5-hydroxypyrazole derivatives as reversible inhibitors of lysine specific demethylase 1.
July 2017, Bioorganic & medicinal chemistry letters,
Chunpu Li, and Mingbo Su, and Wei Zhu, and Weijuan Kan, and Tianpeng Ge, and Gaoya Xu, and Shuni Wang, and Li Sheng, and Feng Gao, and Yunfei Ye, and Jiang Wang, and Yubo Zhou, and Jia Li, and Hong Liu
Crystal structure of human histone lysine-specific demethylase 1 (LSD1).
September 2006, Proceedings of the National Academy of Sciences of the United States of America,
Chunpu Li, and Mingbo Su, and Wei Zhu, and Weijuan Kan, and Tianpeng Ge, and Gaoya Xu, and Shuni Wang, and Li Sheng, and Feng Gao, and Yunfei Ye, and Jiang Wang, and Yubo Zhou, and Jia Li, and Hong Liu
Lysine-Specific Demethylase 1 (LSD1) Inhibitors: Peptides as an Emerging Class of Therapeutics.
October 2023, ACS chemical biology,
Chunpu Li, and Mingbo Su, and Wei Zhu, and Weijuan Kan, and Tianpeng Ge, and Gaoya Xu, and Shuni Wang, and Li Sheng, and Feng Gao, and Yunfei Ye, and Jiang Wang, and Yubo Zhou, and Jia Li, and Hong Liu
Structure activity relationship and modeling studies of inhibitors of lysine specific demethylase 1.
January 2017, PloS one,
Chunpu Li, and Mingbo Su, and Wei Zhu, and Weijuan Kan, and Tianpeng Ge, and Gaoya Xu, and Shuni Wang, and Li Sheng, and Feng Gao, and Yunfei Ye, and Jiang Wang, and Yubo Zhou, and Jia Li, and Hong Liu
Reversible Lysine Specific Demethylase 1 (LSD1) Inhibitors: A Promising Wrench to Impair LSD1.
March 2021, Journal of medicinal chemistry,
Chunpu Li, and Mingbo Su, and Wei Zhu, and Weijuan Kan, and Tianpeng Ge, and Gaoya Xu, and Shuni Wang, and Li Sheng, and Feng Gao, and Yunfei Ye, and Jiang Wang, and Yubo Zhou, and Jia Li, and Hong Liu
Structure-activity studies on N-Substituted tranylcypromine derivatives lead to selective inhibitors of lysine specific demethylase 1 (LSD1) and potent inducers of leukemic cell differentiation.
January 2018, European journal of medicinal chemistry,
Copied contents to your clipboard!